Fenofibric Acid NDC 62332-244

NDC codes

FDA NDC Directory

Product NDC (as listed)62332-244Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62332-0244Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
62332-244-30	62332024430	30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (62332-244-30)Marketed from May 15, 2017
62332-244-90	62332024490	90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (62332-244-90)Marketed from May 15, 2017
62332-244-91	62332024491	1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (62332-244-91)Marketed from May 15, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fenofibric Acid
Generic name (nonproprietary): fenofibric acid
Active ingredients: Fenofibric acid — 45 mg/1
Dosage form: Capsule, Delayed release
Route: Oral
Labeler: Alembic Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208705
Marketing start: May 15, 2017
Listing expires: Dec 31, 2026
Identifiers: Product ID 62332-244_fdb85004-0a66-487a-992c-61764da679b4SPL ID fdb85004-0a66-487a-992c-61764da679b4SPL set ID 8ffcb173-095a-4550-84f2-18959ad2aab8RxCUI 828373, 828379UNII BGF9MN2HU1
Pharmacologic class: Peroxisome Proliferator Receptor alpha Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462332024430 followed by a unit qualifier and the quantity

Package 62332-0244-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 14, 2025.

Indications (excerpt from the label)

Fenofibric acid delayed-release capsules indicated as adjunctive therapy to diet: • to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). • to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. Limitations of Use • Markedly elevated levels of serum TG (e.g., > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been determined [see Warnings and Precautions (5.7)]. • Fenofibrate did not reduce coronary heart disease morbidity and mortality in two…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)